Moderna, Inc.

Moderna: Sell The Cancer Vaccine Hype

Moderna, Progyny, Azenta, Oscar Health, and agilon health Shares Skyrocket, What You Need To Know

A number of stocks jumped in the afternoon session after investors rotated into defensive assets and priced in rising expectations that midterm election outcomes could reverse recent federal spending cuts.

How Investors Are Reacting To Merck (MRK) Phase 3 Melanoma Results

Merck & Co., Inc. is preparing to present Phase 3 melanoma data for its personalized cancer treatment with Moderna, alongside progress in its KRAS inhibitor program, including MK-1084, which previously received Breakthrough Therapy Designation for first line advanced NSCLC with KRAS G12C mutations. The combination of late stage melanoma data with Keytruda and an advancing KRAS pipeline highlights how Merck is trying to broaden its oncology revenue base beyond any single product. We will now...

What's Going On With Moderna Stock Monday?

Moderna shares are trading higher Monday ahead of detailed Phase 3 melanoma data due Saturday and after BofA raised its price target.

Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In

Humacyte, Vera, Maze and Climb Bio will present dialysis-access and kidney-disease findings at ASN Kidney Week.

Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.

It was a head-turning headline. Here's why the market was buzzing.

Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline

BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials.

Phase 3 Cancer Vaccine Success Could Change The Case For Moderna Stock

Moderna was recently added to the Nasdaq-100 Index after positive Phase 3 data for its personalized cancer vaccine with Merck highlighted a pivot toward oncology beyond COVID-focused products. The late-stage success of intismeran positions Moderna's mRNA platform as a potential multi-product franchise across cancer and other conditions rather than a single-therapy story. Next, the focus turns to how this cancer vaccine progress could reshape Moderna's broader investment narrative around...

Moderna Stock Slumps, but It’s Too Early to Panic

Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.

Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know

A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp sell-offs as elevated bond yields restricted market appetite for risk.